Skip to main content
Premium Trial:

Request an Annual Quote

Indivumed, Apceth Partner on Cancer CDx

NEW YORK (GenomeWeb News) – Indivumed and Apceth today announced a partnership to develop technology that can predict patient response to targeted cellular or gene therapies in different cancer types.

The technology, which would allow patients to be stratified based on their response to therapies, would use Indivumed's analytical platform for cancer tissue in order to identify and validate protein biomarkers and targets.

The technology would eventually enable oncologists to identify patients who are best candidates for Apceth's therapeutics, the two companies said.

The project is being funded by the German Federal Ministry of Education and Research as part of the Munich Leading Edge Cluster.

Indivumed is based in Hamburg, Germany and maintains the world's largest tumor database and biobank for the development of new cancer diagnostics, it said. Apceth is headquartered in Much, Germany and develop stem cell and gene therapies.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.